Our studies also demonstrate that afatinib decreases the expression of CSC markers, including CD44 and Oct3/4 in SCC1 and SCC10B cells, and that it reduced the colony- and tumor sphere-forming capability of CSCs. This evidence concerns the gene POU5F1 and neoplasm.